ArticleJournal of cancer research and clinical oncology2025
Conversion therapy and R0 resection for pancreatic cancer with multiple liver metastases: a case report.
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic cancer has a high degree of malignancy, poor prognosis, and short survival time. Surgical resection is the main treatment for pancreatic cancer, but the resection rate is only 20%. Liver metastases are the main reason of unresectable. The conversion therapy for pancreatic cancer with liver metastases is rare and less reported. CASE PRESENTATION: A 52-year-old male patient with pancreatic cancer and multiple liver metastases was reported. Imaging examination showed multiple low-density shadows in the liver. Laboratory tests showed elevated levels of pro-gastrin-releasing peptide and CEA. After gemcitabine combined with albumin-bound paclitaxel chemotherapy, the liver metastases disappeared and the primary pancreatic head tumor was significantly reduced. Pancreaticoduodenectomy was performed, and the patient recovered well without any other adjuvant therapy. The patient has been alive for 36 months without tumor recurrence.
conclusionsThe efficacy of Gemcitabine combined with Albumin-bound paclitaxel in conversion therapy for pancreatic cancer patients with multiple liver metastases may be related to the size and duration of metastases, which needs to be further studied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.